The Aroon Indicator for CIFR entered a downward trend on November 06, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 194 similar instances where the Aroon Indicator formed such a pattern. In 173 of the 194 cases the stock moved lower. This puts the odds of a downward move at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CIFR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CIFR's RSI Indicator exited the oversold zone, 20 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for CIFR just turned positive on November 06, 2026. Looking at past instances where CIFR's MACD turned positive, the stock continued to rise in 44 of 53 cases over the following month. The odds of a continued upward trend are 83%.
Following a +15.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where CIFR advanced for three days, in 238 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
CIFR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.833) is normal, around the industry mean (2.900). P/E Ratio (-2.288) is within average values for comparable stocks, (18.488). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.284). Dividend Yield (0.000) settles around the average of (0.224) among similar stocks. P/S Ratio (35.088) is also within normal values, averaging (139.965).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. CIFR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 98 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CIFR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CMPX advanced for three days, in 230 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CMPX's RSI Oscillator exited the oversold zone, 28 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 55 cases where CMPX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for CMPX just turned positive on October 09, 2026. Looking at past instances where CMPX's MACD turned positive, the stock continued to rise in 37 of 45 cases over the following month. The odds of a continued upward trend are 82%.
CMPX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 19, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CMPX as a result. In 74 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CMPX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for CMPX entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.823) is normal, around the industry mean (3.482). P/E Ratio (-1.946) is within average values for comparable stocks, (-1.183). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (555.556) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. CMPX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CMPX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
CIFR | ||
|---|---|---|
OUTLOOK RATING 1..100 | 55 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 51 Fair valued | |
PROFIT vs RISK RATING 1..100 | 98 | |
SMR RATING 1..100 | 99 | |
PRICE GROWTH RATING 1..100 | 97 | |
P/E GROWTH RATING 1..100 | 7 | |
SEASONALITY SCORE 1..100 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| CIFR | CMPX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 77% | 2 days ago 76% |
| Stochastic ODDS (%) | 2 days ago 86% | 2 days ago 82% |
| Momentum ODDS (%) | N/A | 2 days ago 88% |
| MACD ODDS (%) | 2 days ago 83% | 2 days ago 82% |
| TrendWeek ODDS (%) | 2 days ago 86% | 2 days ago 87% |
| TrendMonth ODDS (%) | 2 days ago 88% | 2 days ago 89% |
| Advances ODDS (%) | 11 days ago 88% | 11 days ago 87% |
| Declines ODDS (%) | 3 days ago 89% | 5 days ago 88% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 76% |
| Aroon ODDS (%) | 2 days ago 89% | 2 days ago 87% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CIFR’s FA Score shows that 1 FA rating(s) are green while CMPX’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CIFR’s TA Score shows that 5 TA indicator(s) are bullish while CMPX’s TA Score has 5 bullish TA indicator(s).
CIFR (@Information Technology Services) experienced а -10.22% price change this week, while CMPX (@Biotechnology) price change was -3.52% for the same time period.
The average weekly price growth across all stocks in the @Information Technology Services industry was -4.90%. For the same industry, the average monthly price growth was -6.00%, and the average quarterly price growth was -14.70%.
The average weekly price growth across all stocks in the @Biotechnology industry was -2.35%. For the same industry, the average monthly price growth was -10.88%, and the average quarterly price growth was -18.54%.
CIFR is expected to report earnings on Mar 02, 2027.
CMPX is expected to report earnings on Feb 26, 2027.
The industry, whose total market cap runs into trillions, makes hardware/software that allows data to be stored, retrieved, transmitted, and manipulated on computers. With the ever-increasing relevance of data, the information technology (IT) industry has gained momentous growth over the years, and continues to thrive on innovation. Some of the behemoths in the industry are International Business Machines Corporation, Accenture, and VMware, Inc.
@Biotechnology (-2.35% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DMO | 9.86 | 0.21 | +2.18% |
| Western Asset Mortgage Opportunity Fund | |||
| FDAT | 21.43 | 0.03 | +0.16% |
| Tactical Advantage ETF (FDAT) | |||
| APUE | 45.45 | 0.07 | +0.16% |
| ActivePassive U.S. Equity ETF (APUE) | |||
| NUMV | 44.77 | -0.18 | -0.40% |
| Nuveen ESG Mid-Cap Value ETF (NUMV) | |||
| FLYD | 41.13 | -0.63 | -1.51% |
| MicroSectors Travel - 3x Inverse Leveraged ETN (FLYD) | |||